We estimated age-standardized cancer incidence (2010–2019) and mortality rates (2010–2022) in the United States to investigate whether cancer rates have increased at younger ages. Fourteen cancers had ...

DuoBody-PD-L1×4-1BB (GEN1046) is a first-in-class bispecific immunotherapy with a manageable safety profile and encouraging preclinical and early clinical activity. With its ability to confer clinical ...

We proved that anlotinib facilitates tumor vessel normalization at least partially through CD4 + T cells, reprograms the immunosuppressive TME into an immunostimulatory TME, significantly inhibits ...

Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRAS G12D) being the most common. Here, we tested the ...

Abstract. Background: Axi-cel is a US and EU-approved autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy for the treatment of adult relapsed/refractory LBCL after ≥ 2 prior lines of ...

AACR Project GENIE has now accrued data from >110,000 tumors, placing it among the largest repository of publicly available, clinically annotated genomic data in the world. GENIE has emerged as a ...

AbstractBackground:. Children living in upstream oil and natural gas (O&G) areas may be exposed to leukemogens and at increased risk for acute lymphoblastic leukemia (ALL).Methods:. We conducted a ...

Pancreatic ductal adenocarcinomas (PDAC) depend on autophagy for survival; however, the metabolic substrates that autophagy provides to drive PDAC progression are unclear. Ferritin, the cellular iron ...

Cancer is clearly a genetic disease, as demonstrated by the complexity of cancer genomes that can carry hundreds of mutations in oncogenes and tumor suppressor genes, collectively known as cancer ...

Abstract. Background: Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10 is irradiated with low-energy thermal neutrons to yield high linear energy ...

Preclinical activity of onvansertib was assessed (i) in vitro in KRAS wild-type and -mutant isogenic colorectal cancer cells and (ii) in vivo, in combination with irinotecan, in a KRAS -mutant ...